Rhythm Pharmaceuticals has just announced that the US Food and Drug Administration (FDA) has approved the MC4R agonist, IMCIVREE™ (setmelanotide) for chronic weight management in adult and paediatric patients 6 years of age and older with obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. This is great news for patients with these disorders and comes on the back of recent clinical trials led by the Farooqi team in the UK in collaboration with colleagues across Europe and the US.
The team is currently running Phase 2 clinical trials to see if Setmelanotide may work in people with other genetic conditions that affect the same pathway.
See further information from Rhythm Pharmaceuticals.
RELATED:
Identification of new genes contributing to early onset obesity
